TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01009099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing retraining
Description: breathing retraining using a metronome

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: treadmill exercise training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: treadmill exercise training
Study: NCT04425330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy exercises
Description: The evidence on the effectiveness of physical therapy in children with myelomeningocele is limited. The International Classification of Functionality, Disability and Health for Children and Youth is a useful tool to assist therapists in analyzing problems about the focus of the intervention. The evidence in physical therapy practice for individuals of all ages with neurological disorders, focuses on 5 Ps: prevention, prediction, participation, personalized and plasticity. Thus, neurological physiotherapists must perform the care with a focus on preventing the patient's disabilities, predicting the ideal response of an intervention, through measures of results of the movement system. In addition, it is of paramount importance that the goal of rehabilitation is that people with neurological disabilities are fully included and participate in life activities that are important to them and that their care is personalized. All of these measures facilitate the process of positive plasticity.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: physiotherapy exercises
Description: The evidence on the effectiveness of physical therapy in children with myelomeningocele is limited. The International Classification of Functionality, Disability and Health for Children and Youth is a useful tool to assist therapists in analyzing problems about the focus of the intervention. The evidence in physical therapy practice for individuals of all ages with neurological disorders, focuses on 5 Ps: prevention, prediction, participation, personalized and plasticity. Thus, neurological physiotherapists must perform the care with a focus on preventing the patient's disabilities, predicting the ideal response of an intervention, through measures of results of the movement system. In addition, it is of paramount importance that the goal of rehabilitation is that people with neurological disabilities are fully included and participate in life activities that are important to them and that their care is personalized. All of these measures facilitate the process of positive plasticity.
Study: NCT03170544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1092, 64 nmol/kg
Description: MK-1092, 64 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine 3.0 nmol/kg
Description: Glargine 3.0 nmol/kg, SC, as a single dose
Study: NCT04425330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PBM
Description: Photobiomodulation occurs from the application of low intensity light such as low intensity laser and light emitting diode (LED). The therapeutic effectiveness of phototherapy is based on the absorption of photons by photoreceptors or chromophores. Studies on the experimental model of spinal cord injury have shown that both wavelengths have the potential to be an effective and non-invasive means of therapy, promoting axonal appearance, increased concentration of glial cells and nerve connections, in addition to functional and sensitive. The findings of a clinical trial involving individuals diagnosed with spinal cord injury demonstrate that PBM exerted positive effects on motor function, especially during isotonic contraction of stimulated muscles assessed by electromyography, and there was a recovery in sensory perception and muscle strength.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SHAM PBM
Description: SHAM PBM
Study: NCT02702401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.90% w/v sodium chloride IV infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Best supportive care will include pain management and management of other potential complications including ascites per local standards of care.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: Best supportive care will include pain management and management of other potential complications including ascites per local standards of care.
Study: NCT01800617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine, Sodium
Study: NCT03846258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low bicarbonate solution (22 mmol/L)
Description: Participants randomized to this arm will be started on CRRT using Phoxillum as the replacement fluid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Bicarbonate solution (32 mmol/L)
Description: Participants randomized to this arm will be started on CRRT using Prismasate as the replacement fluid.
Study: NCT02072967

Intervention type: OTHER
Intervention: Ribomustin
Description: Routine practice

Intervention type: OTHER
Intervention: rituximab
Description: Routine practice
Study: NCT04233970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based intervention programme
Description: The intervention will be designed as an individualized, dialogue-based system that will provide PwMS coordinated, individually tailored information based on the software platform broca®. The intervention programme will consist of three sections:~1. EBPI/decision aid (five modules plus decision aid in case of an acute relapse) provided by the broca® programme. The key element of the EBPI/decision aid is the information on glucocorticosteroids for the treatment of acute relapses.~2. A webinar led via WebEx by a trained MS nurse with questioning/chat session (approx. 60-75min).~3. A supervised chat room provided via the DMSG (https://www.dmsg.de/ms-connect). In addition, email reminders will be used to enhance involvement of participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: web-based information material offered via the same platform (broca®) in addition to usual care
Description: Participants in the control group will have access to web-based information material offered via the same platform (broca®) in addition to usual care. The control group intervention will be based on material of the German Multiple Sclerosis Society (DMSG) on relapse management. The programme will accompany the participants over a period of 4 weeks and a reminder system with neutral e-mail reminders will be used to promote the use of the programme.
Study: NCT02394938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUSIC
Description: In addition to the standard care,patients assigned to the music group will listen recorded classical music. Music will be delivered with a mp3 Player and headphones Music will be listened by the patient in his home.The music play list will be formed by a classical repertoire.During the intervention patients will be recommended to listen to the music for 3 months. Also patients will be asked to listen to the music once or more than once per day, at any time, for a total of 30 minutes per day.Music will be listen at 50-60 decibels below the threshold of 85 db established for listening to portable media devices such as compact disc and MP3 players.Music in this protocol will have a tempo/rhythm in a range of 60-80 beats per minute (bpm).
Study: NCT00178191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bladder diary
Description: 3-day bladder diary

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bladder diary
Description: 3-day bladder diary

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bladder diary
Description: 3-day bladder diary

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Incontinence Quality of Life questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Incontinence Quality of Life questionnaires

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Incontinence Quality of Life questionnaires

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urodynamics
Description: Urodynamics

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urodynamics
Description: Urodynamics

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Urodynamics
Description: Urodynamics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pad weight
Description: Pad weight

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pad weight
Description: Pad weight

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pad weight
Description: Pad weight
Study: NCT03012386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate in G allele carrier
Description: chronic use of phosphodiesterase 5 inhibitor in G allele carrier

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate in non G allele carrier
Description: chronic use of phosphodiesterase 5 inhibitor in Non G allele carrier
Study: NCT03581110

Intervention type: DIAGNOSTIC_TEST
Intervention: computed tomography
Description: noncontrast-enhanced chest computed tomography

Intervention type: DIAGNOSTIC_TEST
Intervention: computed tomography
Description: noncontrast-enhanced chest computed tomography

Intervention type: DIAGNOSTIC_TEST
Intervention: computed tomography
Description: noncontrast-enhanced chest computed tomography
Study: NCT04056559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptable mouthguards
Description: Validate a prototype of Adaptable Intra-Oral Protections patented by Bordeaux University and Bordeaux University Hospital according to 3 levels (ventilation, comfort, cervical muscle activity).
Study: NCT02334228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In SHAPE Lifestyles
Description: In SHAPE Lifestyles is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Club Membership and Education
Description: Fitness club membership with education in using the exercise equipment.
Study: NCT04019041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bermekimab
Description: bermekimab 2 mL (200 mg/mL) pre-filled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bermekimab
Description: bermekimab 2 mL (200 mg/mL) pre-filled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo 2 mL pre-filled syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 2 mL pre-filled syringe
Study: NCT02832869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: short message service based re-education
Description: The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wechat based re-education
Description: The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as Wechat based re-education by one investigator on the day before colonoscopy.
Study: NCT03485235

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ICSI
Description: Intra Cytoplasmic Sperm Injection
Study: NCT04219241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellavita-HD
Description: The participants will receive a total of 12 intravenous administrations of 2x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 180 days (total of 4 cycles).
Study: NCT03151733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single incision laparoscopic surgery
Description: Patients undergo single incision laparoscopic surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: conventional laparoscopic surgery
Description: Patients undergo conventional laparoscopic surgery
Study: NCT03116685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oxabact OC5 - Oxalobacter formigenes HC-1
Description: Active study drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03667469

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic one anastomosis gastric bypass
Description: Laparoscopic surgical bariatric procedure with creation gastric pouch. A jejunal loop was created about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic one anastomosis gastric bypass
Description: Laparoscopic surgical bariatric procedure with creation gastric pouch. A jejunal loop was created about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch.
Study: NCT04599855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 56 mg
Description: Esketamine 56 mg will be self administered as nasal spray.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 84 mg
Description: Esketamine 84 mg will be self administered as nasal spray.
Study: NCT02119546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise and dual-task training
Study: NCT04599855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be self administered as nasal spray.
Study: NCT05135741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pressure bio feedback
Description: The pressure biofeedback unit was placed between the plinth and the posterior aspect of the neck just below the occiput and inflated to a baseline of 20 mmHg. A trained physiotherapist was observing and correcting any substitution movements to ensure that all subjects could perform the exercises correctly. All exercise protocols and programs were taken from previously published studies8-10. A conventional DCF exercise protocol was performed three times a week for four weeks in both groups. The duration of the conventional DCF exercise protocol was 20-30 minutes, once a day in the control group, and 15-20 minutes, once a day in the experimental group

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pressure bio feedback
Description: The pressure biofeedback unit was placed between the plinth and the posterior aspect of the neck just below the occiput and inflated to a baseline of 20 mmHg. A trained physiotherapist was observing and correcting any substitution movements to ensure that all subjects could perform the exercises correctly. All exercise protocols and programs were taken from previously published studies8-10. A conventional DCF exercise protocol was performed three times a week for four weeks in both groups. The duration of the conventional DCF exercise protocol was 20-30 minutes, once a day in the control group, and 15-20 minutes, once a day in the experimental group
Study: NCT01488240

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed dye laser
Description: laser energy
Study: NCT03170544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine 3.0 nmol/kg
Description: Glargine 3.0 nmol/kg, SC, as a single dose
Study: NCT00720161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: daily 850 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: daily 850 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02592902

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical collection of histology specimen
Description: Collection of a histology specimen from the vocal cords and rear laryngeal commissure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical collection of histology specimen
Description: Collection of a histology specimen from the vocal cords and rear laryngeal commissure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Performance of immunohistochemical analysis
Description: Immunohistochemical analysis - presence of pepsin, HPV 6 and 11, HSV 2 and chlamydia trachomasis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Performance of immunohistochemical analysis
Description: Immunohistochemical analysis - presence of pepsin, HPV 6 and 11, HSV 2 and chlamydia trachomasis
Study: NCT03170544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine 3.0 nmol/kg
Description: Glargine 3.0 nmol/kg, SC, as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro 1.2 nmol/kg
Description: Lispro (Humalog®), 1.2 nmol/kg, IV infusion SC over 3 hours as a single dose starting \~12 hours after MK-1092 administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to glargine
Description: Placebo to glargine, SC, as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to glargine
Description: Placebo to glargine, SC, as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to glargine
Description: Placebo to glargine, SC, as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to glargine
Description: Placebo to glargine, SC, as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to glargine
Description: Placebo to glargine, SC, as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to glargine
Description: Placebo to glargine, SC, as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to glargine
Description: Placebo to glargine, SC, as a single dose
Study: NCT02119546

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretch exercise
Description: Stretch exercise \& sitting balance
Study: NCT01032135

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: 2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: 2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
Study: NCT03170544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to glargine
Description: Placebo to glargine, SC, as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to glargine
Description: Placebo to glargine, SC, as a single dose
Study: NCT01032135

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: 2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
Study: NCT03667469

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet therapy
Description: Hypocaloric diet therapy with energy restriction (-500 kcal/d)
Study: NCT01890837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daikenchuto (TU-100)
Description: Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
Study: NCT01032135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: 2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Description: one telephone counseling session per week for 10 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone counseling
Description: one telephone counseling session per week for 10 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Description: one telephone counseling session per week for 10 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) Counseling
Description: One CBT session per week, for 10 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) Counseling
Description: One CBT session per week, for 10 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) Counseling
Description: One CBT session per week, for 10 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medication management
Description: Prescription for naltrexone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medication management
Description: Prescription for naltrexone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive OutPatient Therapy
Description: Return to IOP, group therapy 3 times weekly for about three hours a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive OutPatient Therapy
Description: Return to IOP, group therapy 3 times weekly for about three hours a day.
Study: NCT02581384

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Study: NCT04185168

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: soy isoflavone
Description: 100 mg soy isoflavone (as 2 tablets)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: 2 tablets of placebo
Study: NCT02248090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9496
Description: AZD9496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9496
Description: If initial dosing of AZD9496 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
Study: NCT02366832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Subjects who respond to lidocaine nerve block will undergo CT guided cryoablation of the affected nerve stump with a 17g Galil Medical Ice Sphere cryoablation needle.
Study: NCT02995707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: thalidomide:50mg/d p.o at bedtime